Detalhes bibliográficos
| Resumo: | ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching. |
|---|
| Autores principais: | Fragoso,Yara Dadalti |
|---|
| Outros Autores: | Alves-Leon,Soniza Vieira; Becker,Jefferson; Brooks,Joseph Bruno Bidin; Correa,Eber Castro; Damasceno,Alfredo; Gama,Paulo Diniz da; Gama,Rodrigo Assad da; Matta,Andre Palma da Cunha; Maciel,Ernane Pires; Winckler,Thereza Cristina d’Avila |
|---|
| Assunto: | multiple sclerosis natalizumab fingolimod hydrochloride therapeutics |
|---|
| Ano: | 2016 |
|---|
| País: | Brasil |
|---|
| Tipo de documento: | artigo |
|---|
| Tipo de acesso: | acesso aberto |
|---|
| Instituição associada: | IBICT |
|---|
| Idioma: | inglês |
|---|
| Origem: | Oasisbr |
|---|